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ABSTRACT 29 
Background: Anti-TNF inhibitors successfully improve life quality of patients suffering 30 
from inflammatory disease. Unfortunately, not all patients respond to anti-TNF 31 
therapy and some patients show paradoxical immune side-effects, which is poorly 32 
understood. Surprisingly, anti-TNF agents were shown to promote IL-17A production, 33 
with as yet unknown clinical implications.  34 
 35 
Objective: To investigate the molecular mechanism underlying anti-TNF driven IL-36 
17A expression and the clinical implications of this phenomenon.  37 
 38 
Methods: FACS, RNA-sequencing, RT-qPCR, western blotting, siRNA interference 39 
and kinase-inhibitors, were used to study the molecular mechanism in isolated human 40 
CD4+ T cells from healthy donors. The clinical implication was studied in blood 41 
samples of inflammatory bowel disease (IBD) patients under anti-TNF therapy. 42 
 43 
Results: Here we show that anti-TNF treatment results in inhibition of the anti-44 
inflammatory molecule TNFAIP3/A20 in memory CD4+ T cells.  We found an inverse 45 
relationship between TNFAIP3/A20 expression levels and IL-17A production. 46 
Inhibition of TNFAIP3/A20 promotes kinase activity of p38-MAPK and PKC, which 47 
drives IL-17A expression. Regulation of TNFAIP3/A20 expression and cognate IL-48 
17A production in T cells is specifically mediated via TNFR2-signaling. Ex vivo, in IBD 49 
patients treated with anti-TNF, we found further evidence for an inverse relationship 50 
between TNFAIP3/A20 expression levels and IL-17A producing T cells.  51 
 52 
Conclusion: Anti-TNF treatment interferes in the TNFAIP3/A20 mediated anti-53 
inflammatory feedback-loop in CD4+ T cells and promotes kinase activity. This puts 54 
TNFAIP3/A20, combined with IL-17A expression, on the map as a potential tool in 55 
predicting therapy responsiveness or side effects of anti-TNF therapy. Moreover, it 56 
provides novel targets, related to TNFAIP3/A20 activity, for superior therapeutic 57 
regimens in IBD patients. 58 
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Key Messages: 59 
- Anti-TNF treatment inhibits the anti-inflammatory mediator TNFAIP3/A20 in 60 
activated CD4+ memory T cells. 61 
- Anti-TNF treatment enhances IL-17A production of activated CD4+ memory T cells 62 
by neutralization of TNFα mediated TNFR2-signaling. 63 
- Inhibition of TNFAIP3/A20 expression by anti-TNF or siRNA-inhibition of 64 
TNFAIP3/A20 activated CD4+ enhances IL-17A production. 65 
- P38 MAPK and PKC signaling are required for anti-TNF mediated enhancement of 66 
IL-17A expression in activated CD4+ T cells. 67 
- Increased numbers of IL-17 expressing CD4+ T cells and a concomitant reduction in 68 
TNFAIP3 expression was observed in 50% of IBD patients following anti-TNF therapy. 69 
- Combined TNFAIP3/A20 and IL-17A expression profiling might aid in predicting 70 
therapy responsiveness (or side effects) of anti-TNF therapy. 71 
- This study provides novel targets, related to TNFAIP3/A20 activity, for improved 72 
therapeutic regimens in IBD patients.  73 
  74 
 75 
Capsule Summary: 76 
Anti-TNF treatment interferes in the TNFAIP3/A20 mediated anti-inflammatory 77 
feedback-loop in CD4+ T cells, thereby promoting kinase activity and IL17A 78 
expression. Current findings support patient risk stratification in anti-TNF therapy IBD 79 
patients and provide new therapeutic targets. 80 
 81 
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 84 
Abbreviation:  85 
ADL, Adalimumab 86 
ETN: Etanercept 87 
FVD: Fixable Viability Dye 88 
IFX: Infliximab 89 
rhIL-2: recombinant human Interleukin 2 90 
mIgG: mouse IgG 91 
p38i: p38 MAPK inhibitor  92 
PKCi: PKC inhibitor 93 
rhIgG: Recombinant human IgG  94 
RNA-seq: RNA sequencing 95 
Tmem: CD4+ memory T cell 96 
Tnaïve: CD4+ naïve T cell 97 
TNFAIP3: Tumor necrosis factor alpha-induced protein 3 98 
 99 
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INTRODUCTION  100 
Anti-TNF therapy successfully induces clinical remission, and improvement of quality 101 
of life in many patients affected by auto inflammatory disorders, such as psoriasis, 102 
rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) 1–3. Paradoxically, 103 
anti-TNF treatment of IBD as well as of RA patients has been associated with 104 
unexpected side effects, such as a psoriasis-like syndrome 4,5. This suggests that 105 
depletion of TNFα might inadvertently trigger specific forms of immune pathology, and 106 
highlights the pleiotropic nature of TNFα. This feature has so far received limited 107 
attention. Relevant in this respect is the finding that anti-TNF agents are capable of 108 
promoting IL-17 expression in CD4+ T cell lines from Juvenile Idiopathic Arthritis (JIA) 109 
6 and RA patients 7,8, and can promote monocyte-driven IL-17 production of T cells 7.  110 
As IL-17 is a potent pro-inflammatory cytokine, responsible for the pathogenesis and 111 
progression of psoriasis and many other autoimmune disorders, this may explain 112 
some of the above mentioned clinical findings. Importantly, the molecular mechanism 113 
behind the anti-TNF mediated induction of IL-17 by T cells is as yet not understood, 114 
and the phenomenon has not been clinically evaluated.   115 
TNFα is present in two forms, membrane-bound uncleaved TNFα (~75 kDa) or 116 
soluble cleaved TNFα (~55 kDa). TNFα-signaling through TNF-receptor-1 (TNFR1) or 117 
TNFR2 on immune cells primarily activates NF-κB and promotes transcription of 118 
genes related to inflammatory processes, such as proliferation, cytokine production, 119 
and cell survival 9. Notably, NFκB activation also results in the expression of anti-120 
inflammatory regulators, such as the tumor necrosis factor alpha-induced protein 3 121 
(TNFAIP3), that encodes the deubiquitinating enzyme (DUB) A20 10, a renowned 122 
negative regulator of NFκB activation 11,12. This NFκB-induced TNFAIP3/A20 negative 123 
feedback loop was mostly studied in innate immune cells 13, but there are indications 124 
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that TNFAIP3/A20 also negatively regulates CD4+ T cells14. Polymorphisms in the 125 
TNFAIP3 gene or region have been associated with several autoimmune diseases 15–126 
18 and also anti-TNF responsiveness in IBD and psoriasis 19,20 that suggests an 127 
undetermined relationship between the lack of TNFα-signaling, deviant TNFAIP3/A20 128 
expression and immune activity. 129 
Here, we present evidence that TNFAIP3/A20 acts as master switch in TNFα 130 
blockade-driven IL-17A expression in human CD4+ T cells and showed an inverse 131 
relationship between TNFAIP3/A20 expression levels and IL-17A expressing T cells. 132 
In an ex vivo study of IBD patients treated with the anti-TNF biosimilar Remsima, we 133 
found further evidence for the role of TNFAIP3/A20, by showing that low mRNA levels 134 
of TNFAIP3 were associated with increased IL-17A expression. Reversely, patients 135 
with high TNFAIP3 mRNA levels after Remsima treatment showed low IL-17 136 
expression; most of these patients carried the heterozygous TNFAIP3/A20 region 137 
variant genotype C>G (rs6927172) that has been related to increased TNFAIP3/A20 138 
expression 19. Our results suggest that combined analysis of, TNFAIP3 mRNA 139 
expression, TNFAIP3 region polymorphisms and IL-17A production by CD4+ T cells 140 
may aid the design of future patient risk stratification protocols in anti-TNF therapy. 141 
Moreover, it provides novel targets for additional, improved therapeutic regimens in 142 
IBD patients. 143 
144 
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METHODS 145 
Study approval  146 
The protocols of this study were performed in agreement with the Declaration of 147 
Helsinki and approved by the Institutional Review Board of the Radboud University 148 
Medical Center in Nijmegen (Radboud UMC), the Netherlands. Registration code: 149 
2015-1838. 150 
 151 
Subjects 152 
Voluntary blood donors (Sanquin Bloedvoorziening, Nijmegen, NLD) and healthy 153 
volunteers (n= 31) and patients (n=12) gave written informed consent.  Inflammatory 154 
Bowel Disease patients (ulcerative colitis and Crohn’s disease) were naïve for any 155 
biological drug treatment. For more detailed information on the patients see Table E1 156 
in this article’s Online Repository at http://www.jacionline.org. The clinical evaluation 157 
of IBD patients was based on disease indexes including the Harvey Bradshaw Index 158 
(HBI) for Crohn’s disease and Simple Clinical Colitis Activity Index (SCCAI) for 159 
ulcerative colitis 21. 160 
 161 
Peripheral blood mononuclear cell and T cell isolation  162 
Fresh peripheral blood mononuclear cells (PBMC) collected in tubes with acid citrate 163 
dextrose (ACD) and derived from healthy blood donors, IBD patients were isolated by 164 
Ficoll-paque density gradient centrifugation. Next, CD4+ T cells were isolated using 165 
Rosette Sep CD4 enrichment cocktail (StemCell Technologies) (25-50 μL/ml) 166 
according to the instructions of the supplier. To sort CD4+CD25-CD45RA- (Tmem) 167 
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and CD4+CD25-CD45RA+ (Tnaïve) the purified CD4+ cells were washed and stained 168 
with BD - anti-CD25-BV510 (M-A251, BD), anti-CD45RA- PE (4KB5, Dako), CD4-PE-Cy5.5 169 
(13B8.2, Beckman-Coulter) and FACS-sorted on a FACSAria™ III machine (BD 170 
Biosciences). The purity of the sorted cell populations was >97%. 171 
 172 
Cell culture  173 
RPMI-1640 Dutch modified (Gibco) culture medium, with sodium bicarbonate and 20 174 
mM HEPES, supplemented with penicillin/streptomycin (100 U/mL), sodium pyruvate 175 
(1 mM), glutamine/glutamax and 10% human pooled serum (HPS, Radboud UMC), 176 
was used in all experiments. After cell isolation, 2.5 x 104 cells/well were cultured in 177 
96-well U-bottom plates and incubated with Dynabeads Human T-Activator 178 
CD3/CD28 (1:5, bead: cell ratio) (Gibco) and recombinant human IL-2 (rhIL-2) (100 179 
U/mL) (Proleukin Prometheus Laboratories). Where indicated, cultures were 180 
supplemented with recombinant human (rh) TNFα (rhTNFα, 50 ng/mL, R&D), 181 
rhLymphotoxin-α (rhLTα 10 ng/mL, R&D) or TNFα inhibitors 5 μg/mL, etanercept 182 
(ETN - Enbrel®, Pfizer), infliximab (IFX - Remicade®, Janssen Biotech) or adalimumab 183 
(ADL – Humira®, AbbVie), TNFR2 agonist (2.5 μg/mL, MR2-1, Hycult Biotech), anti-184 
human TNFR1 (10 μg/mL; anti-human CD120a, H398, eBiosicence), anti-human 185 
TNFR2 (10 μg/mL; anti-human CD120b, 3G7A02, Biolegend), recombinant human 186 
IgG1 (rhIgG, AbD18705_hIgG1, Bio-Rad), mouse IgG1 (mIgG, 11711, R&D), or 187 
CysTNFR2 (50 ng/mL) with monoclonal antibodies Mab 80M2 (2 μg/mL) 22. To 188 
examine the effect of pharmaceutical inhibitors of PKC (AEB071, 10 μM; Sotrastaurin, 189 
Novartis) or p38α/β kinase (50 μM, UR13870 previously known as ORG48762-0, 190 
Palau Pharma) 23,24 isolated cells were pre-incubated for 30 min, prior to stimulation.  191 
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 192 
Flow cytometry 193 
Flow cytometry was performed using a 10-colors Navios Flow cytometer (Beckman 194 
Coulter). To evaluate cytokine production, we re-stimulated PBMC and CD4+ T cells 195 
subsets for four hours with PMA (12,5 ng/mL), ionomycin (500 ng/mL) and Brefeldin A 196 
(5 μg/mL) (Sigma-Aldrich). After the incubation, in some cases the cells were stained 197 
with fixable viability dye-APC-780 (FVD, eBioscience) for 30 min, following by surface, 198 
fixation/permeabilization (Intracellular Fixation & Permeabilization Buffer Set, 199 
eBioscience) and intracellular staining.  200 
 201 
Measurement of cell culture cytokines 202 
Cell culture supernatant was analyzed for the presence of IL-17A IFNγ and TNFα 203 
using a Bio-Plex Pro Human Th17 Cytokine Assays (Bio-Rad) according to the 204 
manufacturer’s instruction. The cytokine concentrations were measured using a 205 
Luminex100 machine (Luminex Corp.) and analyzed by the software Bio-Plex 6.1 (Bio-206 
Rad). The lower level detection was 1.9 pg/mL for IL-17A, 11.5 pg/mL for IFNγ and 207 
2.2 pg/mL for TNFα.  208 
 209 
Western Blotting 210 
To detect A20 protein in cultured CD4+ Tmem, the cells were lysed in TBS 211 
Urea/Nonidet-P40/Triton X100 buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 8M 212 
urea, 0.5% NP-40, 0.5% triton X-100, 10mM DTT and cOmplete™ EDTA free 213 
protease inhibitor cocktail Roche) for 30 min on ice and subsequently prepared for 214 
western blot analysis. A20 was detected using a primary mouse anti-human A20 215 
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antibody (59A426, Abcam) (2 μg/mL), followed by a secondary polyclonal goat anti-216 
mouse HRP (P044701-2, Dako). We analyzed expression of the household protein 217 
GAPDH by anti-GAPDH (ab8245, Abcam) to control for protein loading. A 218 
chemiluminescent substrate for HRP (SuperSignal West Femto Maximum Sensitivity 219 
Substrate kit, Thermo Fisher) was used to visualize the proteins using a myECL 220 
Imager system (Bio-Rad).  221 
 222 
Quantitative Real-time PCR (RT-qPCR) 223 
Total RNA was extracted by using the RNeasy Plus Micro kit (Qiagen) followed by 224 
cDNA synthesis using the SuperScript III First-Strand Synthesis System and 225 
Oligo(dT)20 primers (Thermo Fisher Scientific). Taqman gene expression assays 226 
were purchased from Thermo Fisher Scientific (see Table E2 in this article’s Online 227 
Repository at http://www.jacionline.org).  228 
 229 
Single Nucleotide Polymorphism Genotyping 230 
DNA was isolated using the QIAamp DNA Blood Mini Kit according to the 231 
manufacturer's protocol (QIAGEN). SNP genotyping of rs6927172 (for SNP details 232 
see Fig. E1 in this article’s Online Repository at http://www.jacionline.org) was 233 
performed using TaqMan SNP Genotyping Assays on an ABI 7500 system according 234 
to the manufacturer’s instructions using the SNP rs6927172 assay C_1575580_10 235 
(Thermo Fisher Scientific). PCR results were analyzed using 7500 Fast System SDS 236 
software version 1.5 (Thermo Fisher Scientific). 237 
 238 
RNA sequencing (RNA-seq) 239 
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An initial quality check of RNA quantification of the samples was performed by 240 
capillary electrophoresis using the LabChip GX (Perkin Elmer). Non-degraded RNA-241 
samples were selected for subsequent sequencing analysis. We carried out 242 
Differential expression gene (DEG) analysis using DESeq2, where donor and the 243 
batch effect sample preparation were controlled in the model. Principal Component 244 
Analysis (PCA) was carried out to visualize the samples given their entire 245 
transcriptome and any remaining batch effects (see Fig. E2 in this article’s Online 246 
Repository at http://www.jacionline.org). 247 
   248 
siRNA Transfection 249 
For siRNA knockdown of TNFAIP3 Accell SMARTpool siRNA (Dharmacon) was used 250 
according to the manufacturer's instructions. Briefly, 5×104 CD4+ Tmem cells/well 251 
were stimulated with αCD3/CD28 beads (1:5, bead: cell ratio) in Accell delivery media 252 
human serum free (Dharmacon) and incubated with Accell siRNA buffer or 1 μM of 253 
Cyclophilin B (positive control), non-targeting siRNA or TNFAIP3 siRNA for six days 254 
(for siRNA sequences see Table E3 in this article’s Online Repository at 255 
http://www.jacionline.org). RT-qPCR and FACS analysis were performed to confirm 256 
the knockdown and cytokine expression in CD4+ Tmem.  257 
 258 
Statistical analysis 259 
Statistical analysis was performed using GraphPad Prism 5.0 for Windows 260 
(GraphPad Software) and R statistical language. For statistical analysis of 261 
experiments with more than two groups, a Friedman test followed by Dunn's Multiple 262 
comparison was used, while and a Wilcoxon matched-pairs signed rank Test was 263 
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used in case of experiments consisting of two groups. For correlation analysis, we 264 
applied Spearman's rank correlation coefficient. A method based on negative 265 
binomial distribution (DESeq2) was used to test for significant differences in gene 266 
expression for RNA-seq analysis. 267 
For detailed description of materials and methods, please see the article’s Online 268 
Repository at www.jacionline.org. 269 
 270 
RESULTS 271 
Anti-TNF blockade promotes IL-17A expression by CD4+ T in vitro and in vivo in 272 
Inflammatory Bowel Disease patients 273 
The impact of TNF blockade on the function of T lymphocytes is barely understood. 274 
Therefore we first evaluated the in vitro effect of anti-TNF treatment on the pro-275 
inflammatory cytokine producing potential of αCD3/CD28 stimulated PBMC, from 276 
healthy blood donors (HD) and inflammatory bowel diseases (IBD) patients, thereby 277 
focusing on CD4+ T cells. In a first approach, we compared the effects of different 278 
clinically used TNFα-antagonists (infliximab - IFX, adalimumab - ADL and etanercept 279 
– ETN). Inhibition of TNFα, irrespective of the anti-TNF agent tested, resulted in a 280 
significant increased percentage of IL-17A (p < 0.001), IFNγ (p < 0.01), and IL-281 
17A/IFNγ (p < 0.01) expressing CD4+ T cells from healthy individuals (Fig. 1a,b). As 282 
all TNFα antagonists tested induced this same phenomenon, we further focused on 283 
ETN in subsequent analyses. Using ETN, we observed that the in vitro anti-TNF-284 
induced increase in IL-17A and IFNγ expression was also observed in CD4+ T cells 285 
from IBD patients prior to the start of therapy (Fig. 1c). Also anti-TNF induced IL-17 in 286 
Urbano et al 
 
13 
a long-term kinetic assay (See Fig. E3 in this article’s Online Repository at 287 
http://www.jacionline.org). 288 
To verify whether in vivo treatment with anti-TNF agents of patients with inflammatory 289 
disorders revealed a similar phenomenon, we analyzed ex vivo cytokine expression 290 
by PBMC of IBD patients (n=12) that were treated for six weeks with anti-TNF 291 
(Remsima®). Although in RA and ankylosing spondylitis a significant increase in IL-17 292 
expressing cells was previously observed 7,8,25, we did not observe a significant 293 
increase in the absolute number of IL-17A expressing CD4+ T cells from IBD patients, 294 
but we noted that 50% of the patients revealed a clear increase in the number of IL-295 
17A expressing CD4+ T cells (Fig. 1d), while the other patients showed a clear 296 
reduction in IL-17A expression after anti-TNF treatment (Fig. 1d). Patients that 297 
revealed an increase in IL-17A expression did not show an increase in IFNγ 298 
expressing cells (see Fig. E4 in this article’s Online Repository at 299 
http://www.jacionline.org). Moreover, patients that showed an increase in IL-17A 300 
expression following anti-TNF treatment seem to show a better clinical response as 301 
compared to patients showing a reduction in IL-17A expression (Fig. 1d, see Table 302 
E1 in this article’s Online Repository at http://www.jacionline.org).  303 
 304 
Anti-TNF blockade promotes IL-17A production exclusively by ablation of 305 
TNF-signaling in activated CD4+ memory T cells 306 
Next to CD4+ T cells, PBMC contain additional adaptive and innate immune cells that 307 
might also be influenced by anti-TNF agents. To demonstrate that anti-TNF-mediated 308 
cytokine production of CD4+ T cells was a direct consequence of the anti-TNF agent 309 
acting on CD4+ T cells, we FACS-sorted CD4+ naïve (Tnaïve) and CD4+ memory T 310 
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cell (Tmem) based on surface expression of CD45RA and CD25, and cultured the 311 
cells under αCD3/CD28-stimulation in the presence of recombinant human IL-2 (rhIL-312 
2), with and without anti-TNF treatment and analyzed for IL-17A and IFNγ expression 313 
(Fig. 2a).  In isolated Tmem, but not Tnaïve, anti-TNF treatment induced a significant 314 
increase in single IL-17A (p < 0.001), single IFNγ (p < 0.002) and double positive IL-315 
17A/IFNγ producing T cells (p < 0.0036) (Fig. 2b) (Analysis strategy see Fig. E5 in 316 
this article’s Online Repository at http://www.jacionline.org). Isotype control antibodies 317 
did not influence cytokine expression in CD4+ Tmem (see Fig. E6a,b in this article’s 318 
Online Repository at http://www.jacionline.org). In contrast to anti-TNFα, 319 
supplementation of rhTNFα to CD4+ Tmem led to a significant reduction in the 320 
percentage of IL-17A, IFNγ and IL-17A/IFNγ producing T cells compared to the 321 
untreated condition (Fig. 2c). 322 
Likewise, supplementation with recombinant human lymphotoxin-alpha (rhLTα), a 323 
member of the TNF-superfamily that shares amino acid sequence homology with 324 
TNFα and is known to activate the same signaling pathways as TNFα 26, also 325 
inhibited the IL-17A expression of CD4+ Tmem (see Fig. E7 in this article’s Online 326 
Repository at http://www.jacionline.org).  327 
Next, to the observed increase in IL-17A intracellular expression upon anti-TNF 328 
treatment, both IL17A and IL17F mRNA expression levels (Fig. 2d) as well as IL-17A 329 
cytokine secretion in culture supernatants were also increased (see Fig. E8a in this 330 
article’s Online Repository at http://www.jacionline.org). This was neither observed for 331 
IFNG mRNA expression (Fig. 2d), nor for IFNγ secretion (see Fig. E8b in this 332 
article’s Online Repository at http://www.jacionline.org). Th17 and Th1 associated 333 
transcription factors RORC (encoding RORγt) and TBX21 (encoding T-bet) were both 334 
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up-regulated by anti-TNF treatment (Fig. 2d). These data indicate that anti-TNF 335 
treatment promotes a preferential shift towards a Th17 phenotype.  336 
TNFα, either soluble (sTNFα) or membrane-bound TNF (mTNF), signals via the TNF 337 
receptors TNFR1 and/or TNFR2, which ultimately results in NF-κB activation 27. To 338 
confirm that ETN promotes IL-17A expression by inhibition of TNFα-signaling, and not 339 
by mTNF-mediated reverse signaling, we evaluated ETN binding to CD4+ Tmem in 340 
our in vitro system by flow cytometry and demonstrate that ETN does not bind to 341 
Tmem (see Fig. E9 in this article’s Online Repository at http://www.jacionline.org). 342 
This indicates that ETN promotes IL-17A production of in vitro activated CD4+ Tmem 343 
by the prevention of TNFα-signaling rather than by mTNF-mediated reverse signaling. 344 
 345 
TNFα-signaling regulates IL-17A production in CD4+ memory T cells through 346 
TNFR2  347 
Next, we examined which of the TNF receptors is primarily involved in the TNFα-348 
mediated IL-17A regulation of CD4+ Tmem.  First, we evaluated TNFR1 and TNFR2 349 
surface expression on CD4+ Tmem upon αCD3/CD28 stimulation. Freshly isolated 350 
CD4+ Tmem hardly expressed either TNFR1 or TNFR2, while the majority of the cells 351 
showed high expression of TNFR2 after five days of activation; TNFR1 expression at 352 
that time point was barely detectable suggesting that TNFR2, but not TNFR1 might 353 
play a critical role in CD4+ Tmem (see Fig. E10a,b in this article’s Online Repository 354 
at http://www.jacionline.org). To assess via which receptor TNFα influences the IL-355 
17A producing potential of CD4+ Tmem, we isolated and stimulated CD4+ Tmem with 356 
αCD3/CD28 and rhIL-2 in the absence or presence of specific TNFR1 or TNFR2 357 
antagonists. Only TNFR2 inhibition led to an increase in IL-17A expression (Fig. 358 
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3a,b). Reversely, TNFR2 stimulation with a specific TNFR2 agonistic antibodies (Fig. 359 
3a,b) or TNFR2-selective TNF-ligands, cysTNFR2 in presence of the TNFR2-specific 360 
antibody MAb 80M2 (Fig. 3a,b), which ensures full TNFR2 activation 22, led to a 361 
reduction in IL-17A expression (Fig. 3a,b), confirming  that TNFR2-signaling plays a 362 
crucial role in anti-TNF mediated IL-17 expression.  363 
Induction NF-κB activation is one of the main outcomes of TNFα-mediated TNFR- 364 
signaling 28. Anti-TNFR2 treatment or ETN, in contrast to TNFR2 agonist or rhTNFα, 365 
led to strong inhibition of the transcription of NF-κB target genes RELB (Relb), NFKB1 366 
(p50), NFKB2 (p52) and NFKBIA (IκBα) (Fig. 3c,d). 367 
Together, these data demonstrate that TNFR2-signaling plays a significant role in the 368 
regulation of IL-17A production in CD4+ Tmem. Moreover, since anti-TNF agents 369 
suppress the activation of NF-κB signaling pathways, NF-κB does not seem to directly 370 
take part in the enhanced expression of IL-17 by CD4+ Tmem following anti-TNF 371 
treatment. At the same time this suggests that NF-κB might be involved in affecting 372 
factors or processes that negatively regulate IL-17 expression.  373 
 374 
TNF blockade suppresses TNFAIP3/A20 expression, which is associated with 375 
enhanced IL-17A expression in activated CD4+ Tmem 376 
For a more in-depth exploration of factors involved in the increased IL-17A expression 377 
induced by anti-TNF supplementation of αCD3/CD28 stimulated CD4+ Tmem, whole 378 
genome RNA-sequencing was performed. Since supplementation of rhTNFα reduced 379 
the IL-17A secreting potential of CD4+ Tmem, this condition was co-analyzed to 380 
establish differential gene expression between both conditions. The comparative 381 
analysis of CD4+ Tmem exposed to anti-TNF (ETN) versus rhTNFα revealed 382 
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opposing transcriptional profiles (Fig. 4a). Of the 751 differentially expressed genes 383 
(DEG) (FDR=0.05) between rhTNFα and anti-TNF comparison (For the full DEG list 384 
see Table E4 in this article’s Online Repository at http://www.jacionline.org), 385 
TNFAIP3 (tumor necrosis factor alpha-induced protein 3, encoding A20 protein), 386 
NFKBIA (IκBα), RELB (Relb), BIRC2 (baculoviral IAP repeat containing 2) and LTA 387 
(LTα) were suppressed by anti-TNFα (Fig. 4b), while AQP3 (aquaporin 3), SLFN5 388 
(Schlafen family member 5), IL7R (IL-7R), APOL4 (apolipoprotein L4) and ITGA6 389 
(integrin α6) were significantly upregulated (Fig. 4b).  390 
The deubiquitinating enzyme (DUB) TNFAIP3/A20 is a well-known negative regulator 391 
of NFκB activation 11,12. Activation of NFκB (i.e. by TNFα) enables translocation of 392 
NFκB into the nucleus and subsequent target gene activation and protein expression 393 
including the anti-inflammatory regulator TNFAIP3/A20 10. The deubiquitinating 394 
activity of TNFAIP3/A20 ultimately avoids the assembly of proximal NF-κB-activating 395 
complexes and stops the inflammatory response, triggering an NF-κB auto-regulatory 396 
negative feedback loop 29. Therefore, of the DEG with a fold change >= 2 (red dot 397 
plots) from the total of 751 genes identified, we focused on the regulation of 398 
TNFAIP3/A20 by anti-TNF since TNFAIP3 is implicated in the pathology of several 399 
autoimmune diseases 15–18. Moreover, TNFAIP3/A20 has been shown to negatively 400 
regulate CD4+ T cell activation 14. 401 
Using RT-qPCR we confirmed that anti-TNF (ETN) supplementation to cultures of 402 
αCD3/CD28 stimulated CD4+ Tmem suppressed TNFAIP3 mRNA, while on the 403 
contrary T cell activation in the presence of rhTNFα induced TNFAIP3 transcription 404 
(Fig. 4c).  Also, we demonstrated that TNFAIP3 mRNA expression inversely 405 
correlated with IL17A expression (Spearman test, r= -0.7789, p<0.001) in activated 406 
CD4+ Tmem upon anti-TNF and rhTNFα treatment (Fig. 4d). Then, we analyzed if the 407 
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observed down-regulation of TNFAIP3 by anti-TNF (ETN) also resulted in reduced 408 
protein expression of its cognate protein A20 (˜87 kD). To this end, isolated CD4
+ 409 
Tmem were stimulated with αCD3/CD28 beads and rhIL-2 was added exogenously in 410 
the presence or absence of rhTNFα or anti-TNF (ETN) and after five days of culture 411 
the cells were harvested and prepared for western blot analysis. Anti-TNF treatment 412 
clearly inhibited TNFAIP3/A20 protein expression, while conversely the addition of 413 
rhTNFα, led to a significant increase of TNFAIP3/A20 (Fig. 4e).  414 
To reveal a direct relationship between suppression of TNFAIP3/A20 and the 415 
increased IL-17A expression, we used a siRNA approach to knockdown 416 
TNFAIP3/A20 in isolated CD4+ Tmem. We demonstrate that TNFAIP3-siRNA resulted 417 
in significantly enhanced percentages of IL-17A expressing cells (Fig. 4f). Using RT-418 
qPCR we confirmed that TNFAIP3-siRNA inhibition led to a suppression of 419 
TNFAIP3/A20 mRNA expression (Fig. 4g). The data implicate TNFAIP3/A20 as an 420 
essential regulator of IL-17A in CD4+ Tmem, and reveal the association between anti-421 
TNF-mediated repression of TNFAIP3/A20 and enhancement of IL-17A expression. 422 
Moreover, in IBD patients that showed increased IL-17A production after anti-TNF 423 
therapy (Fig. 1d), we found a reduced frequency of the heterozygous TNFAIP3/A20 424 
region variant genotype C>G (rs6927172) (Fig. 4h), which has been shown to 425 
increase TNFAIP3 expression in IBD 19, corroborating the reduced TNFAIP3/A20 426 
mRNA expression in CD4+ Tmem (Fig. 4i). These observations further support the 427 
clinical relevance of our finding, i.e. deviant TNFAIP3/A20 expression plays an 428 
important role in IL- 17A expression by CD4+ Tmem via down-modulation of TNF-429 
mediated signaling. 430 
 431 
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PKC and p38 MAPK-signaling are required for anti-TNF-mediated enhancement 432 
of IL-17A expression in stimulated CD4+ memory T cells. 433 
In the experiments above, we stimulated T cells by triggering both the T cell receptor 434 
(CD3) and co-stimulatory receptor CD28 by αCD3/CD28 beads.  PKC-theta (PKC-θ) 435 
signaling, which plays an important role in T cell activation by αCD3/CD28 activation 436 
30 has also been implicated in the regulation of the biological activity of A20 in 437 
activated T cells and vice versa 14. Furthermore, PKC signaling has also been shown 438 
to contribute to IL-17 production in mouse T cells 31 and human CD4+ Treg 32. 439 
Interestingly, in our RNA-sequencing analysis (see Table E4 in this article’s Online 440 
Repository at http://www.jacionline.org) we observed that anti-TNF treatment induced 441 
expression of PRKCQ (encoding PKC-θ) in αCD3/CD28 stimulated CD4+ Tmem, 442 
which we confirmed by RT-qPCR (Fig. 5a). We hypothesized that inhibition of the 443 
PKC-signaling of CD4+ Tmem, which was activated in the presence of 444 
ETN/αCD3/CD28 beads, may prevent the anti-TNF mediated increase in IL-17A 445 
expression. Supplementation of the pan-PKC inhibitor AEB071 (sotrastaurin, PKCi) to 446 
CD4+ Tmem that were activated by αCD3/CD28 beads in the presence of anti-TNF 447 
(ETN), prevented the anti-TNF mediated increase in IL-17A expression (Fig. 5b,c). 448 
These results suggest that PKC-signaling, most likely as a consequence of TCR and 449 
CD28 co-stimulation, plays an important role in the anti-TNF mediated increase in IL-450 
17A expression. However, it is not likely that proximal PKC-signaling is the main 451 
driver of anti-TNF mediated IL-17 expression in these activated T cells, rather a more 452 
distal signaling pathways will be involved. To further explain the enhanced IL-17A 453 
expression by anti-TNF treatment, we focused on the MAPK signaling pathway, as 454 
TNFAIP3/A20 has been implicated in the negative regulation of p38 MAPK inhibitor 33 455 
and recently p38 was shown to control IL-17 expression in mouse CD4+ T cells 34. 456 
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Small molecule p38 MAPK inhibition (p38i) in CD4+ Tmem cells activated in the 457 
presence of anti-TNF (ETN), prevented the anti-TNF mediated increase in IL-17 458 
expression (Fig. 5b,d). This indicates that p38-signaling is vital in anti-TNF mediated 459 
enhancement of IL-17A expression.  460 
In summary, prevention of TNFα-signaling by anti-TNF in αCD3/CD28 stimulated 461 
CD4+ Tmem results in increased IL-17A production by inhibition of the anti-462 
inflammatory mediator TNFAIP3/A20. Under these circumstances, PKC and p38 463 
MAPK are crucial for the production of IL-17A. On the basis of our findings, and as 464 
depicted in Fig. 6 we propose a model illustrating the molecular pathways that are 465 
involved in anti-TNF treatment mediated enhancement of IL-17A expression in CD4+ 466 
T cells. 467 
 468 
DISCUSSION 469 
Anti-TNF therapy is successful in many patients with inflammatory disorders 35, but 470 
anti-TNF therapy is also associated with adverse effects such as the unexplained 471 
psoriasis-like syndrome 4,36. These paradoxical observations following inhibition of 472 
TNFα-signaling might be explained by the pleiotropic nature of TNFα that displays 473 
both inflammatory and anti-inflammatory bioactivities5. So far, more detailed 474 
mechanistic insight in how these phenomena are induced is limited, and clinical data 475 
supporting such findings are lacking.  476 
Here, we present novel insights, showing that inhibition of TNFα-signaling by anti-477 
TNF agents in activated CD4+ memory T cells prevents expression of the anti- 478 
inflammatory mediator TNFAIP3/A20, which consequently promotes IL-17A 479 
production. This process requires PKC and p38 MAPK-signaling. 480 
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TNFAIP3/A20, encoded by TNFAIP3 is a ubiquitin-editing enzyme consisting of an 481 
A20-type zinc finger and an OTU domain, which mediates ubiquitin ligase and 482 
deubiquitinase activity, respectively 33. TNFAIP3/A20 acts as a negative feedback 483 
mechanism mainly by preventing NF-κB activation through deubiquitination or 484 
ubiquitination of a multitude of proteins such as RIP1 37. Although it is well 485 
established that TNFAIP3/A20 regulates TNFα-signaling 38, TNFAIP3/A20 has been 486 
shown to regulate multiple other immune pathways including TLR-signaling 39–41, IL-487 
17R-signaling 33, Wnt-signaling42, TCR-signaling 14 and MAPK-signaling 33. Not 488 
surprisingly, loss of TNFAIP3/A20 expression causes spontaneous inflammatory and 489 
autoimmune diseases in mice 43, and polymorphisms or mutations in TNFAIP3 gene 490 
or region that affect A20 expression or function are related to a variety of autoimmune 491 
diseases in humans 13. Interestingly, clinical studies showed that TNFAIP3 region 492 
polymorphisms are associated with therapeutic efficacy of anti-TNF treatment in IBD 493 
as well as psoriasis patients 19,20, indicating an unresolved relationship between the 494 
lack of TNFα-signaling, deviant A20 expression and immune activity. Here, using 495 
RNA-seq and western blot analyses, we add to the understanding of this relationship 496 
by demonstrating that anti-TNF treatment prevents transcription and expression of the 497 
anti-inflammatory mediator TNFAIP3/A20 in activated CD4+ Tmem, and we 498 
subsequently provide evidence that siRNA-inhibition of TNFAIP3 results in increased 499 
IL17A expression.  500 
The impact of TNFAIP3/A20 ablation on the exacerbated expression of IL-17A by 501 
CD4+ Tmem following anti-TNF therapy in the clinical setting is still unknown.  Here, 502 
in a small cohort of IBD patients treated with the anti-TNF biological Remsima, we 503 
showed an inverse relationship between numbers of IL-17A- expressing CD4+ Tmem 504 
and a reduction of TNFAIP3/A20 mRNA expression, supporting our in vitro findings.  505 
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Notably, IBD patients treated with Remsima showing increased numbers of IL-17A 506 
expressing CD4+ T cells upon treatment, seemed to have a better clinical response. 507 
Also, this group revealed a lower frequency of the heterozygous TNFAIP3 region 508 
variant genotype C>G (rs6927172), which previously was shown to increase 509 
TNFAIP3/A20 expression, and which was associated with non-responsiveness to 510 
anti-TNF therapy in IBD patients 19. These findings clearly suggest a link between IL-511 
17A expression by CD4+ T cells, TNFAIP3/A20 region polymorphisms, TNFAIP3 512 
expression levels and clinical responsiveness to anti-TNF therapy. To firmly establish 513 
this link, further studies are needed.  514 
Until now, a relationship between TNFAIP3/A20 expression and IL-17A production by 515 
activated T cells had not been established.  Upon T cell stimulation, TNFAIP3/A20 is 516 
strictly regulated in order to control the process of T cell activation; TNFAIP3/A20 is 517 
highly expressed in resting CD4+ T cells and rapidly depleted after TCR/CD28 518 
stimulation 14 in a process involving both PKC-θ and paracaspase MALT1 activity 44,45, 519 
which ultimately leads to activation of NF-κB. However, under persistent stimulation, 520 
TNFAIP3/A20 is restored and abolishes TCR and NF-κB-signaling 14.  Our data reveal 521 
that the inhibition of TNFAIP3 expression, either via blocking of TNFα or via TNFAIP3 522 
knockdown, in activated CD4+ Tmem results in increased IL-17A expression in vitro. 523 
To our knowledge, this link between TNFAIP3/A20 and IL-17 has not been described 524 
before. However, from mice studies it is known that A20 can prevent MAPK activity 33, 525 
while p38 MAPK activity appeared essential for IL-17 production by CD4+ T cells in an 526 
experimental allergic encephalomyelitis (EAE) model 34. Although we did not evaluate 527 
the direct relation between inhibition of A20 and p38 MAPK activity in our experiments, 528 
our data show that p38 MAPK inhibition prevented anti-TNF-mediated enhancement 529 
of IL-17A expression by activated CD4+ Tmem. Together, this supports the possibility 530 
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that ablation of TNFAIP3/A20 by anti-TNF treatment, endorses p38 MAPK activity, 531 
thereby promoting in IL-17A expression in CD4+ Tmem.  532 
Besides its function as a regulator of TCR-signaling in T cell activation, there is strong 533 
evidence that TNFAIP3/A20 is an important negative regulator of activation of antigen 534 
presenting cells (APCs) in mice 46. Anti-TNF treatment was shown to result in much 535 
stronger production of IL-17 in an in vitro experimental setup where human T cells 536 
were stimulated with αCD3 mAb plus monocytes, as compared to T cells that were 537 
activated with αCD3/CD28-stimulation beads only 7. This indicates that the presence 538 
of APCs even further boosts IL-17 expression following depletion of TNFα by anti-539 
TNF agents. A possible explanation for this increased IL-17 expression upon 540 
monocyte co-culture is that anti-TNF agents might suppress TNFAIP3/A20 541 
expression in these APC resulting in hyper-activated APC, which in turn provoke 542 
hyper-stimulation of CD4+ Tmem, thereby triggering high IL-17 expression. In fact, 543 
TNFAIP3/A20 deprivation of dendritic cells (DC) in mice led to exacerbated DC 544 
activation and these DC strongly promoted overproduction of IL-17 by mouse wild-545 
type T cells in vitro 47. A limitation of our work is that we only focus on T cells as a 546 
source of TNF, but obviously there are many other cellular sources of TNF 48 that 547 
are influenced by anti-TNF treatment. Next to T cells, also other immune cell types 548 
such as basophils and ILC3 were associated with IBD 49,50. 549 
In which ways might our findings that TNFAIP3/A20 acts as master switch in TNFα 550 
blockade-driven IL-17A expression add to improved clinical regimens? IL-17A 551 
producing T cells are strongly associated with various inflammatory diseases 51–53. It 552 
could well be that the anti-TNF therapy associated reduction in TNFAIP3/A20 and its 553 
resultant increase in IL-17A expressing T cells contributes to the immune pathology of 554 
paradoxical autoimmune related side effects, such as psoriasis-like syndrome that are 555 
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observed in 0.6-5% of the patients treated with anti-TNF medication 4. Of interest, in 556 
pilot experiments we observed that CD4+ memory T cells of IBD patients that 557 
developed a psoriasis-like syndrome following anti-TNF treatment in the past, 558 
revealed reduced TNFAIP3/A20 mRNA expression levels and an increased potential 559 
to express IL-17A as compared to healthy controls or IBD patients that did not 560 
develop psoriasis-like syndrome (see Fig. E12 in this article’s Online Repository at 561 
http://www.jacionline.org). TNFAIP3/A20 has been shown to prevent p38 MAPK 562 
activity in a mouse model 34, and we here demonstrate that anti-TNF induced 563 
inhibition of TNFAIP3/A20 promotes IL-17A expression by facilitating p38 MAPK 564 
activity. Although speculative, anti-TNF treatment combined with specific p38 MAPK-565 
inhibition might prevent the anti-TNF associated paradoxical autoimmune side effects. 566 
In addition, our data suggest that IL-17A expression and reduced TNFAIP3/A20 567 
mRNA levels by activated CD4+ T cells might contribute to better clinical response in 568 
IBD patients treated with anti-TNF. 569 
Although IL-17A is renowned for its pro-inflammatory potential, IL-17 has also been 570 
shown to be beneficial in epithelial barrier protection in IBD 54–57. Additional support 571 
for a protective role of IL-17A in IBD emerged from a placebo-controlled anti-IL-17A 572 
monoclonal antibody clinical trial in Crohn's disease, where it was reported that a 573 
substantial number of the patients developed exacerbation of disease 58. Although 574 
anti-IL-17 inhibition was not successful in IBD, small-molecule inhibition of RORyt, a 575 
crucial transcription factor for Thelper-17 cell differentiation, might be an alternative 576 
approach for the treatment of IBD 59. Moreover, next to anti-TNF inhibition other 577 
biological-based therapeutics, such as adhesion-molecule inhibition are successfully 578 
applied in IBD 60. 579 
Based on our current work we propose that combined analysis of TNFAIP3 mRNA 580 
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expression, TNFAIP3 region polymorphisms and IL-17A production by CD4+ T cells 581 
may aid the design of future patient risk stratification protocols in anti-TNF therapy. 582 
Moreover, it provides novel TNFAIP3/A20-activity related targets for additional 583 
improved therapeutic regimens in IBD patients. 584 
In conclusion, we add to the understanding of the biological effects of anti-TNF 585 
therapy by demonstrating that TNF blockade interferes in an autocrine anti-586 
inflammatory regulatory feedback loop with TNFAIP3/A20 at its heart and resulting in 587 
enhanced IL-17A production.   588 
 589 
DATA AVAILABILITY 590 
Raw and processed data from RNA-seq have been deposited in the European 591 
Bioinformatics Institute (EMBL-EBI) database, under accession number E-MTAB-592 
5622 (at http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5622).  593 
 594 
ACKNOWLEDGMENTS 595 
The authors thank the FACTT network (Cost Action BM1305: http://www.afactt.eu) for 596 
supporting this work by positive discussion. We also thank Pieter van der Vlies from 597 
the Genome Analysis Facility (University Medical Center Groningen) for conducting 598 
the RNA-seq analysis. 599 
 600 
CONTRIBUTIONS 601 
Urbano et al 
 
26 
P.C.M.U., A.K.H, I.J. and H.J.P.M.K. designed research; P.C.M.U., H.T., R.A.G., A.A. 602 
and B.H. performed research; H.T., A.A., A.K.H., Y.L., and R.A.G. contributed new 603 
reagents/analytic tools; F.K. and L.S. carried out clinical evaluation of the patients; 604 
P.C.M.U., I.J., H.J.P.M.K., Y.L. and R.A.G. analyzed data; P.C.M.U., I.J.  V.F.A., 605 
A.K.H. and H.J.P.M.K prepared the manuscript, and P.C.M.U., I.J. and H.J.P.M.K 606 
wrote the final manuscript. All the authors reviewed the paper. 607 
 608 
REFERENCES 609 
1. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. 610 
Journal of drugs in dermatology : JDD 8, 546–59 (2009). 611 
2. Seymour HE, Worsley A, Smith JM, Thomas SH. Anti-TNF agents for 612 
rheumatoid arthritis. British journal of clinical pharmacology 51, 201–8 (2001). 613 
3. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF 614 
Therapy in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis 10, 615 
989–997 (2016). 616 
4. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with 617 
TNF-blockade therapy: a review and analysis of 127 cases. The Journal of 618 
dermatological treatment 20, 100–8 (2009). 619 
5. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or 620 
exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory 621 
bowel disease: a systematic literature review based on 222 cases. Journal of 622 
Crohn’s & colitis 7, 517–24 (2013). 623 
6. Maggi L, Cimaz R, Capone M, Santarlasci V, Querci V, Simonini G, et al. Brief 624 
report: etanercept inhibits the tumor necrosis factor α-driven shift of Th17 625 
lymphocytes toward a nonclassic Th1 phenotype in juvenile idiopathic arthritis. 626 
Arthritis & rheumatology (Hoboken, N.J.) 66, 1372–7 (2014). 627 
7. Evans HG, Roostalu U, Walter GJ, Gullick NJ, Frederiksen KS, Roberts CA, et 628 
al. TNF-α blockade induces IL-10 expression in human CD4+ T cells. Nature 629 
communications 5, 3199 (2014). 630 
8. Aerts NE, De Knop KJ, Leysen J, Ebo DG, Bridts CH, Weyler JJ, et al. 631 
Increased IL-17 production by peripheral T helper cells after tumour necrosis 632 
factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-633 
associated chemokine receptor expression. Rheumatology 49, 2264–2272 634 
(2010). 635 
Urbano et al 
 
27 
9. Schütze, S, Wiegmann, K, Machleidt T, Krönke M. TNF-induced activation of 636 
NF-kappa B. Immunobiology 193, 193–203 (1995). 637 
10. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation 638 
and immunity. The Journal of biological chemistry 284, 8217–21 (2009). 639 
11. Shembade N, Harhaj EW. Regulation of NF-κB signaling by the A20 640 
deubiquitinase. Cellular & molecular immunology 9, 123–30 (2012). 641 
12. Martin F, Dixit VM. A20 edits ubiquitin and autoimmune paradigms. Nature 642 
genetics 43, 822–3 (2011). 643 
13. Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity 644 
and human disease. Nature Reviews Immunology 12, 774–785 (2012). 645 
14. Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, et al. A20 646 
negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 647 
ubiquitin chains. Journal of immunology (Baltimore, Md. : 1950) 182, 7718–28 648 
(2009). 649 
15. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two 650 
independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nature 651 
Genetics 39, 1477–1482 (2007). 652 
16. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, et al. 653 
Multiple polymorphisms in the TNFAIP3 region are independently associated 654 
with systemic lupus erythematosus. Nature genetics 40, 1062–4 (2008). 655 
17. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et 656 
al. Genome-wide association study of 14,000 cases of seven common diseases 657 
and 3,000 shared controls. Nature 447, 661–78 (2007). 658 
18. Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genome-659 
wide association studies. Discovery medicine 10, 177–83 (2010). 660 
19. Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, et al. 661 
Associations between functional polymorphisms in the NFκB signaling pathway 662 
and response to anti-TNF treatment in Danish patients with inflammatory bowel 663 
disease. The Pharmacogenomics Journal 14, 526–534 (2014). 664 
20. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, et al. 665 
TNFAIP3 gene polymorphisms are associated with response to TNF blockade 666 
in psoriasis. The Journal of investigative dermatology 132, 593–600 (2012). 667 
21. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, 668 
et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and 669 
Future Directions. Clinical Gastroenterology and Hepatology 14, 348–354.e17 670 
(2016). 671 
22. Krippner-Heidenreich A, Tübing F, Bryde S, Willi S, Zimmermann G, Scheurich 672 
P. Control of receptor-induced signaling complex formation by the kinetics of 673 
ligand/receptor interaction. The Journal of biological chemistry 277, 44155–63 674 
Urbano et al 
 
28 
(2002). 675 
23. Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, et al. A 676 
potent and selective p38 inhibitor protects against bone damage in murine 677 
collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. 678 
British journal of pharmacology 154, 153–64 (2008). 679 
24. Galan-Arriero I, Avila-Martin G, Ferrer-Donato A, Gomez-Soriano J, Piazza S, 680 
Taylor J, et al. Early treatment with UR13870, a novel inhibitor of p38α 681 
mitogenous activated protein kinase, prevents hyperreflexia and anxiety 682 
behaviors, in the spared nerve injury model of neuropathic pain. Neuroscience 683 
Letters 604, 69–74 (2015). 684 
25. Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC, et al. Anti-685 
tumour necrosis factor treatment increases circulating T helper type 17 cells 686 
similarly in different types of inflammatory arthritis. Clinical & Experimental 687 
Immunology 181, 401–406 (2015). 688 
26. Upadhyay V, Fu YX. Lymphotoxin signalling in immune homeostasis and the 689 
control of microorganisms. Nature Reviews Immunology 13, 270–279 (2013). 690 
27. Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the 691 
treatment of rheumatic diseases. Nature Reviews Rheumatology 13, 217–233 692 
(2017). 693 
28. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune 694 
diseases. Nature Reviews Drug Discovery 9, 482–493 (2010). 695 
29. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 696 
(TNFAIP3) is a central regulator of immunopathology. Trends in Immunology 30, 697 
383–391 (2009). 698 
30. Chand S, Mehta N, Bahia MS, Dixit A, Silakari O. Protein kinase C-theta 699 
inhibitors: a novel therapy for inflammatory disorders. Current pharmaceutical 700 
design 18, 4725–46 (2012). 701 
31. Tan SL, Zhao J, Bi C, Chen XC, Hepburn DL, Wang J, et al. Resistance to 702 
experimental autoimmune encephalomyelitis and impaired IL-17 production in 703 
protein kinase C theta-deficient mice. Journal of immunology (Baltimore, Md. : 704 
1950) 176, 2872–9 (2006). 705 
32. He X, Koenen HJPM, Smeets RL, Keijsers R, van Rijssen E, Koerber A, et al. 706 
Targeting PKC in Human T Cells Using Sotrastaurin (AEB071) Preserves 707 
Regulatory T Cells and Prevents IL-17 Production. Journal of Investigative 708 
Dermatology 134, 975–983 (2014). 709 
33. Garg AV, Ahmed M, Vallejo AN, Ma A, Gaffen SL. The deubiquitinase A20 710 
mediates feedback inhibition of interleukin-17 receptor signaling. Science 711 
signaling 6, ra44 (2013). 712 
34. Noubade R, Krementsov DN, Del Rio R, Thornton T, Nagaleekar V, Saligrama 713 
N, et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and 714 
Urbano et al 
 
29 
autoimmune encephalomyelitis. Blood 118, 3290–300 (2011). 715 
35. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, 716 
present and future. International Immunology 27, 55–62 (2015). 717 
36. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and 718 
psoriasiform lesions during anti-TNF therapy: a review. Seminars in arthritis and 719 
rheumatism 37, 251–5 (2008). 720 
37. Catrysse L, Vereecke L, Beyaert , van Loo G. A20 in inflammation and 721 
autoimmunity. Trends in Immunology 35, 22–31 (2014). 722 
38. Bikker R, Christmann M, Preuß K, Welz B, Friesenhagen J, Dittrich-Breiholz O, 723 
et al. TNF phase III signalling in tolerant cells is tightly controlled by A20 and 724 
CYLD. Cellular Signalling 37, 123–135 (2017). 725 
39. Shi CS, Kehrl JH. TRAF6 and A20 Regulate Lysine 63-Linked Ubiquitination of 726 
Beclin-1 to Control TLR4-Induced Autophagy. Science Signaling 3, ra42-ra42 727 
(2010). 728 
40. Shembade N, Ma A, Harhaj E. W. Inhibition of NF-kappaB signaling by A20 729 
through disruption of ubiquitin enzyme complexes. Science (New York, N.Y.) 730 
327, 1135–9 (2010). 731 
41. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The 732 
ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor 733 
responses. Nature Immunology 5, 1052–1060 (2004). 734 
42. Shao L, Oshima S, Duong B, Advincula R, Barrera J, Malynn BA, et al. A20 735 
Restricts Wnt Signaling in Intestinal Epithelial Cells and Suppresses Colon 736 
Carcinogenesis. PLoS ONE 8, e62223 (2013). 737 
43. Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, et al. Combined 738 
Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic 739 
Opportunity in Rheumatoid Arthritis: Development and Characterization of a 740 
Novel Bispecific Antibody. Arthritis & Rheumatology 67, 51–62 (2015). 741 
44. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annual review 742 
of immunology 20, 761–94 (2002). 743 
45. Afonina IS, Elton L, Carpentier I, Beyaert R. MALT1 - a universal soldier: 744 
multiple strategies to ensure NF-κB activation and target gene expression. 745 
FEBS Journal 282, 3286–3297 (2015). 746 
46. Xuan NT, Wang X, Nishanth G, Waisman A, Borucki K, Isermann B, et al. A20 747 
expression in dendritic cells protects mice from LPS-induced mortality. 748 
European Journal of Immunology 45, 818–828 (2015). 749 
47. Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, et al. The 750 
ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of 751 
apoptotic cells, and systemic autoimmunity. Immunity 35, 82–96 (2011). 752 
Urbano et al 
 
30 
48. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. 753 
Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and 754 
TNF-α: Receptors, functions, and roles in diseases. Journal of Allergy and 755 
Clinical Immunology 138, 984–1010 (2016). 756 
49. Chapuy L, Bsat M, Mehta H, Rubio M, Wakahara K, Van VQ, et al. Basophils 757 
increase in Crohn disease and ulcerative colitis and favor mesenteric lymph 758 
node memory TH17/TH1 response. Journal of Allergy and Clinical Immunology 759 
134, 978–981 (2014). 760 
50. Konya V, Czarnewski P, Forkel M, Rao A, Kokkinou E, Villablanca EJ, et al. 761 
Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 762 
3 innate lymphoid cells. Journal of Allergy and Clinical Immunology 1–14 (2016). 763 
doi:10.1016/j.jaci.2017.01.045 764 
51. Bartlett HS, Million RP. Targeting the IL-17–TH17 pathway. Nature Reviews 765 
Drug Discovery 14, 11–12 (2014). 766 
52. Huh JR, Littman DR. Small molecule inhibitors of RORγt: targeting Th17 cells 767 
and other applications. European journal of immunology 42, 2232–7 (2012). 768 
53. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. 769 
Phenotypic and functional features of human Th17 cells. The Journal of 770 
experimental medicine 204, 1849–61 (2007). 771 
54. Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. 772 
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial 773 
Permeability. Immunity 43, 727–738 (2015). 774 
55. Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. 775 
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal 776 
Immunoregulation. Immunity 43, 739–750 (2015). 777 
56. Fuss IJ. IL-17: intestinal effector or protector? Mucosal Immunology 4, 366–367 778 
(2011). 779 
57. Whibley N, Gaffen SL. Gut-Busters: IL-17 Ain’t Afraid of No IL-23. Immunity 43, 780 
620–2 (2015). 781 
58. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins 782 
PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for 783 
moderate to severe Crohn’s disease: unexpected results of a randomised, 784 
double-blind placebo-controlled trial. Gut 61, 1693–700 (2012). 785 
59. de Wit J, Al-Mossawi MH, Hühn MH, Arancibia-Cárcamo CV, Doig K, Kendrick 786 
B, et al. RORγt inhibitors suppress TH17 responses in inflammatory arthritis 787 
and inflammatory bowel disease. Journal of Allergy and Clinical Immunology 788 
137, 960–963 (2016). 789 
60. Davis BP, Ballas ZK. Biologic response modifiers: Indications, implications, and 790 
insights. Journal of Allergy and Clinical Immunology 139, 1445–1456 (2017). 791 
 792 
Urbano et al 
 
31 
Fig. 1. Anti-TNF promotes IL-17 expression in vitro and ex vivo in inflammatory bowel disease patients 793 
treated with anti-TNF therapy. Flow cytometry of IL-17A and IFNɣ expression of PBMC from healthy controls 794 
that were stimulated with αCD3/CD28 beads and IL-2 in the absence or presence of anti-TNF agents. Intracellular 795 
IL-17A and IFNɣ expression were measured on day five of the cultures after 4 hours restimulation with PMA and 796 
ionomycin in the presence of Brefeldin-A. a. Representative dot plots gated on CD4
+
 T cells showing IFNγ and IL-797 
17A expression. b. Cumulative data showing the percentage of single and double positive IL-17A and IFNɣ-798 
producing CD4
+
 T cells cultured for 5 days in the presence of TNF antagonists; infliximab (IFX), adalimumab 799 
(ADL) or etanercept (ETN) (n=6). c. Percentage of single and double positive IL-17A and IFNɣ-producing CD4
+
 T 800 
cells from healthy control donors (HD) (n=6) and IBD patients (n= 13) that were cultured as indicated. d. Ex vivo 801 
analysis of the absolute number of IL-17A-expressing CD4
+
 T cells from IBD patients upon anti-TNF treatment 802 
(remsima) (n=12). Based on the ex vivo IL-17A expression in PBMC, detected after 4 hours of restimulation with 803 
PMA and ionomycin in the presence of Brefeldin-A, the patients were grouped in those who showed reduced (IL-804 
17) or increased (IL-17) IL-17A expression after remsima treatment (middle graphs), followed by their clinical 805 
response (lower graph).  All data are shown as mean ± SEM. For statistical analysis the Friedman test followed by 806 
Dunn’s Multiple Comparison test, Wilcoxon matched-pairs signed rank test and Two-way ANOVA were used, P-807 
value < 0.05 (*), < 0.01 (**), ns= no significant.  808 
 809 
 810 
Fig. 2. Anti-TNF blockade promotes IL-17A production exclusively by ablation of TNFα-signaling in 811 
activated CD4
+ 
memory T cells. a. Representative dot plots showing the FACS-sort strategy of CD25
-
CD45RA
-
 812 
(Tmem), CD25
-
CD45RA
+
 (Tnaïve) CD4
+
 T cells from healthy controls. b. Cumulative data showing the expression 813 
of single IL-17A, single IFNγ and IL-17A/IFNγ co-expressing Tnaïve (n=6) or Tmem (n=11). Isotype control 814 
analysis is shown in Fig. E6 in the article’s Online Repository at www.jacionline.org. c. Cumulative data plot 815 
showing the percentage of single IL-17A, single IFNγ and IL-17A/IFNγ co-expressing CD4
+
 Tmem that were 816 
stimulated as indicated in the presence of recombinant human TNFα (rhTNFα) (n=11). d. Relative mRNA 817 
expression levels of IL17A, IL17F, IFNG, RORC and TBX21 in CD4
+ 
Tmem that were cultured as indicated and 818 
measured by RT-qPCR (n=8). All data are shown as mean ± SEM. For statistical analysis Friedman test followed 819 
by Dunn’s Multiple Comparison test, Wilcoxon matched-pairs signed rank test and Two-way ANOVA were used. 820 
P-value < 0.05 (*), < 0.01 (**), < 0.01 (***), ns= no significant.  821 
 822 
 823 
Fig. 3. TNFR2-signaling, not TNFR1, plays a critical role in regulating IL-17A-expression in CD4
+
 memory T 824 
cells. Flow cytometry of IL-17A expression of FACS-sorted CD4
+
 Tmem from healthy donors that were stimulated 825 
with αCD3/CD28-beads and IL-2 in the absence or presence of TNF-receptor antagonists (anti-TNFR2, anti-826 
TNFR1) (n=7) or TNFR2 agonist (n=9) or cysTNFR2 plus 80M2 (n=6), or rhTNFα or anti-TNF (ETN) (n=8) and 827 
cultured for five days. a. Representative FACS dot plots showing CD3
+
 IL-17A expressing cells and b. cumulative 828 
data showing intracellular IL-17A
+ 
expression in CD4
+
 Tmem after restimulation with PMA and ionomycin in the 829 
presence of Brefeldin-A (n=6-9). c and d, Relative mRNA expression measured by RT-qPCR of NFκB target 830 
genes in CD4
+ 
Tmem that were cultured for 4 days in the presence of TNFR2 agonist, or anti-TNFR2 (n=5) or 831 
rhTNFα or anti-TNF (ETN). All data are shown as mean ± SEM. Friedman test followed by Dunn’s Multiple 832 
Comparison test and Wilcoxon matched-pairs signed rank test were used for statistical analysis. P-value < 0.05 (*), 833 
< 0.01 (**), ns= no significance. 834 
 835 
 836 
 837 
Fig. 4. TNFAIP3/A20 plays a central role in anti-TNF-mediated enhancement of IL-17 expression in 838 
activated CD4
+
 memory T cells. RNA-sequencing of healthy blood donor derived FACS-sorted CD4
+ 
Tmem that 839 
were activated with αCD3/CD28 beads and   IL-2 in the presence of recombinant human TNFα (rhTNFα) or anti-840 
TNF (ETN) for three days. a. Representative heat map from 751 differentially expressed genes (DEG) obtained 841 
from DESeq2 analysis (FDR at 5%, adjusted p <= 0.05) is shown (n=4). b. Cumulative volcano plot showing the 842 
fold change in DEG when CD4
+
 Tmem was activated in the presence of ETN or rhTNFα. Red dots refer to genes 843 
with a >= 2 fold change (n=4). c. Relative mRNA expression of TNFAIP3 in CD4
+
 Tmem that were activated for 844 
four days in the presence of rhTNFα or ETN (n=6). d. Spearman's rank correlation coefficient of mRNA expression 845 
of TNFAIP3 vs IL17A. e. Western blot (WB) analysis showing the cytoplasmic expression of A20 in CD4
+
 Tmem, 846 
household protein expression of GAPDH is included. e. Cumulative data showing the relative protein expression of 847 
A20 normalized to GAPDH expression (n=4). The original WB membranes are shown in the Fig. E11. f. FACS 848 
analysis of the IL-17A expression in activated CD4
+
 Tmem where TNFAIP3 was inhibited by siRNA-based 849 
approach (n=5). g. TNFAIP3 mRNA inhibition by TNFAIP3 siRNA (n=5). All data are shown as mean ± SEM. h. 850 
Single SNP analysis of rs6927172 on IBD patients, those who showed reduced (IL-17) or increased (IL-17) IL-851 
17A expression after Remsima treatment (n=12), and their i. relative mRNA expression of TNFAIP3 in FACS-852 
sorted cryopreserved CD4
+
 Tmem (n=6).  DESeq2, Friedman test followed by Dunn’s Multiple Comparison Test, 853 
Wilcoxon-Mann-Whitney U Test and Spearman test were used for statistical analysis. P-value < 0.05 (*), < 0.01 854 
(**), ns= no significance. 855 
 856 
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 857 
Fig. 5. Protein kinase C and p38 MAPK are required for anti-TNF-mediated enhancement of IL-17A 858 
expression in stimulated CD4
+
 memory T cells. a.  RT-qPCR of PRKCQ by CD4
+
 Tmem that were stimulated 859 
with αCD3/CD28 and IL-2 in the absence or presence of rhTNFα or anti-TNF (ETN) for four days (n=8). b. Flow 860 
cytometry of the intracellular IL-17A expression of CD4
+
 Tmem that were activated with or without anti-TNF (ETN) 861 
in the absence or presence of PKC or p38 inhibitors (PKCi and p38i) for five days. Representative flow cytometry 862 
dot plots are shown. Aggregate flow cytometry data showing the effect of c. PKC inhibition (n=10) and d. p38 863 
inhibition (n=6) on IL-17A expression. Data show mean ± SEM. Statistical significance was analysed by the 864 
Wilcoxon matched-pairs signed rank test and Friedman test followed by Dunn’s Multiple Comparison Test. P-value 865 
< 0.05 (*) and < 0.001 (***). 866 
 867 
 868 
Fig. 6. Model showing the involvement of the anti-inflammatory regulator A20 in anti-TNF mediated 869 
expression of IL-17A by activated CD4
+
 T cells.  870 
a. Upon T cell receptor activation and CD28 costimulation (1) TNFα is secreted (2) and signals via TNFR2 to 871 
promote NFκB expression (3) that leads to high expression of the anti-inflammatory mediator A20 (4) which is 872 
known to act as negative feedback loop to suppressing NFκB (5). Our results indicate that A20 may inhibit 873 
p38MAPK and PKC activity (6) and prevents IL-17A (7) expression. 874 
 875 
b. Anti-TNF inhibits TNFα-signaling via TNFR2 (2) and as a consequence A20 is not expressed (4). Lack of A20 876 
impair NFκB negative feedback loop (5) and endorses PKC and p38 MAPK-signaling (6), inducing expression of 877 
IL-17 (7).  878 
  879 
c. Stratification of anti-TNF responsiveness in IBD patients (blue represent the group of patients with high IL-17 880 
expression after anti-TNF treatment and red represents the group of patients with low IL-17 expression after anti-881 
TNF treatment) based on intracellular IL-17A production by T cells, followed by TNFAIP3 mRNA expression and 882 
polymorphisms. 883 
